![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The study met both primary and secondary efficacy endpoint measures ACT-541468 (Daridorexant) significantly improved sTST from baseline compared to placebo at 28 days (p<0.001 for 50 mg, p=0.042 for 25 mg).
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: ACT-541468
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per sachet.
Lead Product(s): Macrogol
Therapeutic Area: Gastroenterology Product Name: Movicol HD
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: EA Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022